The obesity-drug industry has developed a wonderfully seductive habit: whenever one hormone pathway works, add another one.
That strategy produced tirzepatide, which hits GIP and GLP-1 receptors. It produced retatrutide, which adds glucagon. And now Eli Lilly is showing what happens when tirzepatide meets eloralintide, an experimental amylin-receptor agonist. The answer, at least in Phase 2, is more weight loss — and a reminder that human physiology keeps receipts.
The 23.3% Headline Comes With a 27% Complication
Results presented September 30 at the European Association for the Study of Diabetes meeting showed that the highest-dose combination of eloralintide and tirzepatide produced an estimated average 23.3% reduction in body weight after 48 weeks. The figure came from an efficacy analysis estimating the results had participants remained on treatment. The trial randomized 367 adults with obesity or overweight and type 2 diabetes. The tirzepatide-only group lost 14.8%, while the highest-dose eloralintide-only group lost 11.1%, according to Lilly and STAT. A lower, 6-mg eloralintide-only dose achieved 12.3%. In a population with diabetes, where weight-loss percentages often trail those seen in people without diabetes, 23.3% is a serious number.
So is 27%.
That was the upper end of treatment discontinuation due to adverse events across the combination groups, compared with 2.9% for tirzepatide alone. Discontinuation rates ranged from 10.8% to 27.0% across the combination regimens, with gastrointestinal side effects a major issue. Those figures varied by regimen and dose and should not be assumed to describe the same treatment arm that achieved the highest weight loss. The exact interpretation requires care because Phase 2 exists partly to learn how to dose a drug. But it punctures the simplistic narrative that more receptors automatically equal a better medicine.
The Next Obesity War Is About Optimization
The next obesity war is increasingly about optimization, not merely efficacy. If a therapy can drive extraordinary weight loss but a meaningful fraction of patients cannot stay on it, the headline percentage becomes less useful in the real world. A drug that produces somewhat less weight loss but is easier to tolerate may outperform commercially and clinically because people actually keep taking it.
Lilly understands this better than almost anyone. Its pipeline now resembles a portfolio built to cover different versions of the same metabolic problem: injectable incretins, oral small molecules, triple agonists, amylin programs and combinations. The company does not need one molecule to be perfect if it can own the menu.
Amylin Is Becoming Pharma’s Favorite New Lever
Eloralintide is especially interesting because amylin is emerging as the industry’s favorite new lever. Amylin is co-secreted with insulin and participates in satiety and gastric signaling. Novo Nordisk has its own amylin strategy through cagrilintide and CagriSema. Zealand Pharma and Roche are advancing petrelintide. Lilly is now testing whether adding amylin signaling to its already formidable tirzepatide platform can push efficacy further.
It can, apparently. The harder question is whether patients will want the full package.
A Bigger Number Does Not Automatically Mean a Better Medicine
There is a tendency in obesity-drug coverage to treat the highest weight-loss number like a 40-yard-dash time. But medicines are not combine prospects. The best therapy is not automatically the one that wins a single metric. It has to balance efficacy, tolerability, adherence, safety, cost, route of administration and what happens after years rather than 48 weeks.
There is another distinction worth keeping clear. Tirzepatide is an approved medicine, but EloraTZP, the combination of tirzepatide and eloralintide, remains investigational. In the Phase 2 study, the two treatments were administered as separate injections. Lilly plans to advance a combined formulation into Phase 3 with an optimized dose-escalation schedule. Whether that can preserve the weight-loss benefit while reducing treatment discontinuations remains an open question.
The Side-Effect Bill Is Part of the Story
That is why the discontinuation data deserve to sit in the same paragraph as the 23.3% figure.
Both are the story.
The industry spent the last few years proving it could make obesity drugs dramatically more powerful. The next few may be spent discovering exactly how much power patients can comfortably use.
